



A Phase 2 Clinical Trial Evaluating AMG 714 Treatment for Vitiligo

Study Locations & Contacts:

Yale University, New Haven, CT:

Andrea DeClement
andrea.decllement@yale.edu
203-785-5182

UC Irvine, Irvine, CA:

Laura Ortiz
ulloal@hs.uci.edu
714-308-4124

UC Davis, Davis, CA:

Angela Calaguas
Tel: (916) 551-2636
acalaguas@ucdavis.edu

Tufts Medical Center, Boston, MA:

Nicole Dumont
ndonovan1@tuftsmedicalcenter.org
(617) 636-7462

Henry Ford Health System, Detroit, MI:

Angie Parks-Miller
AMILLER5@hfhs.org
313-916-0426

Jennifer Creasor
JCreaso2@hfhs.org
313-916-0427

Coming Soon:

UMass Medical School, Worcester, MA:

Celia Hartigan
Celia.Hartigan@umassmed.edu
774-455-4756

Northwell Health, Lake Success, NY:

Emma Grace Lao
elao1@northwell.edu
516-881-7037

About Vitiligo and AMG 714:

- Vitiligo is an autoimmune disorder in which some of your body's immune cells, called T cells, attack melanocytes (the pigment producing cells in the

skin). This leads to patches of skin depigmentation (loss of normal skin color). Scientists believe that specific T cells, called tissue resident memory T cells (Trm), are involved in the attack on melanocytes. Trm cells depend on the chemical signal IL-15. Therefore, scientists believe that interrupting the IL-15 signal might lead to a decrease in Trm cells, which might make vitiligo better.

- AMG 714 is an experimental drug that interferes with IL-15 and may stop the immune system's attack on melanocytes and allow the melanocytes to produce normal color in the skin (repigmentation).

What do participants need to know?

- Eligible participants will be randomly assigned to one of two groups: One group will receive the study drug, AMG 714; the other group will receive an inactive substance called a placebo.
- This study is double-blinded, which means that during the study, neither you nor your study doctor will know who is receiving AMG 714 or placebo.
- The treatment period is 12 weeks long, consisting of 6 clinic visits with subcutaneous doses every 2 weeks
- The follow-up period is approximately 36 weeks, during which there are 5 clinic visits
- During the follow-up period, participants may require Narrowband Ultraviolet B light (nbUVB) phototherapy treatment for approximately 24 weeks which will be provided at no cost

You may be eligible to participate in the REVEAL study if you:

- Are between the ages of 18 and 75
- Have been diagnosed with vitiligo by a dermatologist
- Have a noticeable amount of vitiligo both on your face and on your body
- Are willing to stop other treatments for vitiligo

To learn more, contact the site(s) above, or visit the REVEAL website at:

<http://www.revealstudy.org>